Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
PD-L1 biomarker testing guides cancer treatment decisions. These results are difficult to access because laboratory reports are unstructured and require clinical expertise to interpret.
GlobalData on MSN2d
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancerThe US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback